Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 7, 2013, Pages 1696-1705

  Li, Xin Min ^a   Tang, Wai Hong Wilson ^a   Mosior, Marian K ^c   Huang, Ying ^a   Wu, Yuping ^d   Matter, William ^c   Gao, Vivian ^a   Schmitt, David ^a   DiDonato, Joseph A ^a   Fisher, Edward A ^d   Smith, Jonathan D ^a   Hazen, Stanley L ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CLEVELAND STATE UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Cholesterol efflux; High density lipoprotein cholesterol; Macrophage; Prognosis

Indexed keywords

ABC TRANSPORTER A1; ALBUMIN; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EFFUSION; HEART INFARCTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INCIDENCE; ISOTOPE LABELING; LIPID ANALYSIS; MACROPHAGE; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT;

CHOLESTEROL EFFLUX; HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL; MACROPHAGE; PROGNOSIS;

AGED; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL LINE; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOPRECIPITATION; INCIDENCE; LOGISTIC MODELS; MACROPHAGES; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OHIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; STROKE; TIME FACTORS;

EID: 84879113852     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301373     Document Type: Article

References (33)

1. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature. 2005;438:612-621.
2. Rosenson RS, Brewer HB Jr., Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-1919.
3. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-232.
4. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-580.
5. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
6. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253-1263.
7. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
8. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346.
9. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
10. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
11. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1-and SR-BI-mediated cholesterol efflux. J Lipid Res. 2005;46:2246-2253.
12. Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, Fagerberg B, Camejo G. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res. 2008;49:481-490.
13. Travis AJ, Kopf GS. The role of cholesterol efflux in regulating the fertilization potential of mammalian spermatozoa. J Clin Invest. 2002;110:731-736.
14. Ha JS, Ha CE, Chao JT, Petersen CE, Theriault A, Bhagavan NV. Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. Biochim Biophys Acta. 2003;1640:119-128.
15. Brown MS, Goldstein JL. The receptor model for transport of cholesterol in plasma. Ann N Y Acad Sci. 1985;454:178-182.
16. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375.
17. Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD. Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:1460-1465.
18. de Vries R, Groen AK, Dullaart RP. Cholesterol efflux capacity and atherosclerosis. N Engl J Med. 2011;364:1473-1474; author reply 1474.
19. Chirinos JA, Zambrano JP, Chakko S, Schob A, Goldberg RB, Perez G, Mendez AJ. Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation. 2005;112:2446-2453.
20. de Vries R, Groen AK, Perton FG, Dallinga-Thie GM, van Wijland MJ, Dikkeschei LD, Wolffenbuttel BH, van Tol A, Dullaart RP. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis. 2008;196: 733-741.
21. Nestel P, Hoang A, Sviridov D, Straznicky N. Cholesterol efflux from macrophages is influenced differentially by plasmas from overweight insulinsensitive and -resistant subjects. Int J Obes (Lond). 2012;36:407-413.
22. Brennan ML, Reddy A, Tang WH, Wu Y, Brennan DM, Hsu A, Mann SA, Hammer PL, Hazen SL. Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation. 2010;122:70-79.
23. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176-1184.
24. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol. 2009;29:1383-1391.
25. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009;53:2061-2067.
26. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
27. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181-2187.
28. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol. 2007;27:1828-1836.
29. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F, Kovanen PT. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem. 2004;279:9930-9936.
30. Kane JP, Malloy MJ. Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol. 2012;23:367-371.
31. Guey LT, Pullinger CR, Ishida BY, O'Connor PM, Zellner C, Francone OL, Laramie JM, Naya-Vigne JM, Siradze KA, Deedwania P, Redberg RF, Frost PH, Seymour AB, Kane JP, Malloy MJ. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol. 2011;108:360-366.
32. de Vries R, Perton FG, van Tol A, Dullaart RP. Carotid intima media thickness is related positively to plasma pre s-high density lipoproteins in nondiabetic subjects. Clin Chim Acta. 2012;413:473-477.
33. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, Kinter M. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005;280:38-47.